143 results on '"Dumyati G"'
Search Results
2. Inpatient costs, mortality and 30-day re-admission in patients with central-line-associated bloodstream infections
- Author
-
Stevens, V., Geiger, K., Concannon, C., Nelson, R.E., Brown, J., and Dumyati, G.
- Published
- 2014
- Full Text
- View/download PDF
3. Risk factors for community-associated Clostridioides difficile infection in young children
- Author
-
Weng, M. K., primary, Adkins, S. H., additional, Bamberg, W., additional, Farley, M. M., additional, Espinosa, C. C., additional, Wilson, L., additional, Perlmutter, R., additional, Holzbauer, S., additional, Whitten, T., additional, Phipps, E. C., additional, Hancock, E. B., additional, Dumyati, G., additional, Nelson, D. S., additional, Beldavs, Z. G., additional, Ocampo, V., additional, Davis, C. M., additional, Rue, B., additional, Korhonen, L., additional, McDonald, L. C., additional, and Guh, A. Y., additional
- Published
- 2019
- Full Text
- View/download PDF
4. Vital Signs: Improving Antibiotic Use Among Hospitalized Patients
- Author
-
Fridkin, S., Baggs, J., Fagan, R., Magill, S., Pollack, L. A., Malpiedi, P., Slayton, R., Khader, K., Rubin, M. A., Jones, M., Samore, M. H., Dumyati, G., Dodds-Ashley, E., Meek, J., Yousey-Hindes, K., John Jernigan, Shehab, N., Herrera, R., Clifford Mcdonald, L., Schneider, A., and Srinivasan, A.
- Subjects
Hospitalization ,Safety Management ,Databases, Factual ,Clostridioides difficile ,Drug Resistance, Bacterial ,Humans ,Articles ,Patient Safety ,Centers for Disease Control and Prevention, U.S ,Practice Patterns, Physicians' ,Enterocolitis, Pseudomembranous ,United States ,Anti-Bacterial Agents - Abstract
Background Antibiotics are essential to effectively treat many hospitalized patients. However, when antibiotics are prescribed incorrectly, they offer little benefit to patients and potentially expose them to risks for complications, including Clostridium difficile infection (CDI) and antibiotic-resistant infections. Information is needed on the frequency of incorrect prescribing in hospitals and how improved prescribing will benefit patients. Methods A national administrative database (MarketScan Hospital Drug Database) and CDC’s Emerging Infections Program (EIP) data were analyzed to assess the potential for improvement of inpatient antibiotic prescribing. Variability in days of therapy for selected antibiotics reported to the National Healthcare Safety Network (NHSN) antimicrobial use option was computed. The impact of reducing inpatient antibiotic exposure on incidence of CDI was modeled using data from two U.S. hospitals. Results In 2010, 55.7% of patients discharged from 323 hospitals received antibiotics during their hospitalization. EIP reviewed patients’ records from 183 hospitals to describe inpatient antibiotic use; antibiotic prescribing potentially could be improved in 37.2% of the most common prescription scenarios reviewed. There were threefold differences in usage rates among 26 medical/surgical wards reporting to NHSN. Models estimate that the total direct and indirect effects from a 30% reduction in use of broad-spectrum antibiotics will result in a 26% reduction in CDI. Conclusions Antibiotic prescribing for inpatients is common, and there is ample opportunity to improve use and patient safety by reducing incorrect antibiotic prescribing. Implications for Public Health Hospital administrators and health-care providers can reduce potential harm and risk for antibiotic resistance by implementing formal programs to improve antibiotic prescribing in hospitals.
- Published
- 2014
5. NAP1 Strain Type Predicts Outcomes From Clostridium difficile Infection
- Author
-
See, I., primary, Mu, Y., additional, Cohen, J., additional, Beldavs, Z. G., additional, Winston, L. G., additional, Dumyati, G., additional, Holzbauer, S., additional, Dunn, J., additional, Farley, M. M., additional, Lyons, C., additional, Johnston, H., additional, Phipps, E., additional, Perlmutter, R., additional, Anderson, L., additional, Gerding, D. N., additional, and Lessa, F. C., additional
- Published
- 2014
- Full Text
- View/download PDF
6. Clostridium difficile in the Pediatric Population of Monroe County, New York
- Author
-
Rhee, S. M., primary, Tsay, R., additional, Nelson, D. S., additional, van Wijngaarden, E., additional, and Dumyati, G., additional
- Published
- 2014
- Full Text
- View/download PDF
7. Cumulative Antibiotic Exposures Over Time and the Risk of Clostridium difficile Infection
- Author
-
Stevens, V., primary, Dumyati, G., additional, Fine, L. S., additional, Fisher, S. G., additional, and van Wijngaarden, E., additional
- Published
- 2011
- Full Text
- View/download PDF
8. An organization-wide approach to decreasing central venous catheter bloodstream infections: Applying lessons learned from intensive care surveillance to general patient care units
- Author
-
Greene, L., primary, Farnsworth, D., additional, Sposato, K., additional, Lovejoy, G., additional, and Dumyati, G., additional
- Published
- 2005
- Full Text
- View/download PDF
9. Evaluation of Cold-Adapted, Reassortant Influenza B Virus Vaccines in Elderly and Chronically III Adults
- Author
-
Treanor, J., primary, Dumyati, G., additional, O'Brien, D., additional, Riley, M. A., additional, Riley, G., additional, Erb, S., additional, and Betts, R., additional
- Published
- 1994
- Full Text
- View/download PDF
10. Antivirals for Influenza: What Is Their Role in the Older Patient?
- Author
-
Dumyati, G. and Falsey, A.R.
- Subjects
- *
INFLUENZA , *IMMUNIZATION , *RESPIRATORY syncytial virus , *PARAINFLUENZA viruses , *ANTIVIRAL agents - Abstract
Influenza infection is a cause of high morbidity and mortality in the elderly living in the community or in long-term care facilities. Yearly immunisation is the most important means for prevention of infection. However, protection by vaccination in the elderly is incomplete, and influenza infections and outbreaks in long-term care facilities still occur. Symptoms of influenza include fever, chills, headache, myalgia and respiratory symptoms. These clinical features overlap considerably with other co-circulating respiratory viruses such as respiratory syncytial virus and parainfluenza virus. Elderly and debilitated patients with influenza may present with less prominent respiratory symptoms and may present only with fever, lassitude and confusion. Antiviral prophylaxis and treatment with amantadine and rimantadine have been given in the past but adverse effects and early development of drug resistance have limited their use. The newer antivirals zanamivir and oseltamivir are equally effective and have the advantage of being well tolerated and active against both influenza A and B without the development of resistance. However, they are costly. Early identification and diagnosis of influenza illnesses are crucial since treatment with antiviral agents should be started within 48 hours of the beginning of illness. [ABSTRACT FROM AUTHOR]
- Published
- 2002
11. Clinical and Laboratory Characteristics of Invasive Infections Due to Methicillin-Resistant Staphylococcus aureusIsolates Demonstrating a Vancomycin MIC of 2 Micrograms per Milliliter: Lack of Effect of Heteroresistant Vancomycin-Intermediate S. aureusPhenotype
- Author
-
Satola, S. W., Lessa, F. C., Ray, S. M., Bulens, S. N., Lynfield, R., Schaffner, W., Dumyati, G., Nadle, J., and Patel, J. B.
- Abstract
ABSTRACTWe describe clinical and laboratory characteristics of invasive methicillin-resistant Staphylococcus aureus(MRSA) infections with vancomycin MICs of 2 µg/ml and compare heteroresistant-intermediate S. aureus(hVISA) to non-hVISA. Health care-associated community-onset infections were the most common and resulted in frequent complications and relapses. hVISA-infected patients were more likely to have been hospitalized in the year prior to MRSA culture.
- Published
- 2011
- Full Text
- View/download PDF
12. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly.
- Author
-
Treanor, John J., Mattison, H. Reid, Dumyati, Ghinwa, Yinnon, Amos, Erb, Shirley, Dolin, Raphael, Betts, Robert F., Treanor, J J, Mattison, H R, Dumyati, G, Yinnon, A, Erb, S, O'Brien, D, Dolin, R, and Betts, R F
- Subjects
INFLUENZA vaccines ,INFLUENZA ,OLDER people - Abstract
Objective: To evaluate the efficacy of adding intranasal live attenuated cold-adapted influenza A vaccine to inactivated influenza vaccine to prevent influenza A in elderly residents of long-term-care institutions.Design: Randomized, double-blind, placebo-controlled study conducted over 3 years.Setting: Three large nursing homes.Participants: A total of 523 residents of nursing homes (mean age, 84.2 years).Interventions: All participants received trivalent inactivated influenza vaccine parenterally and were randomly assigned to receive either live attenuated influenza A (H3N2) virus vaccine or placebo intranasally.Measurements: Laboratory-documented influenza A was defined as a respiratory illness plus isolation of influenza A virus from nasal secretions, significant serologic response, or both. Participants were considered to have been exposed to influenza A if they resided in an institution in which cases of influenza A were documented. Outbreak-associated illnesses were defined as those occurring between the first and last isolation of influenza virus from within the institution, +/- 3 days.Results: Participants who received intranasal vaccine and were subsequently exposed to influenza A had significantly lower rates of laboratory-documented influenza A (9 of 162 vaccine recipients compared with 24 of 169 placebo recipients; vaccine protective efficacy, 60.6%; 95% CI, 18% to 82%), outbreak-associated respiratory illnesses (13 of 162 vaccine recipients compared with 34 of 169 placebo recipients; vaccine protective efficacy, 56.8%; CI 23% to 76%), and outbreak-associated influenza-like illnesses (6 of 162 vaccine recipients compared with 18 of 169 placebo recipients; vaccine protective efficacy, 65.0%; CI 17% to 86%).Conclusions: Intranasal immunization with live attenuated influenza A virus vaccine provided additional protection against influenza A when added to parenteral trivalent inactivated influenza vaccine among elderly nursing home residents. [ABSTRACT FROM AUTHOR]- Published
- 1992
- Full Text
- View/download PDF
13. 10 Years after NNIS; the Use of Comparative Data as a Catalyst for Organizational Improvement
- Author
-
Greene, L.R., Farnsworth, D., and Dumyati, G.
- Published
- 2006
- Full Text
- View/download PDF
14. If First You Don't Succeed: Re-Analyze the Data or: Drilling down Dialysis Data
- Author
-
Farnsworth, D.L., Greene, L., and Dumyati, G.
- Published
- 2006
- Full Text
- View/download PDF
15. Trends in U.S. Burden of Infection and Outcomes.
- Author
-
Guh, A. Y., Mu, Y., Winston, L. G., Johnston, H., Olson, D., Farley, M. M., Wilson, L. E., Holzbauer, S. M., Phipps, E. C., Dumyati, G. K., Beldavs, Z. G., Kainer, M. A., Karlsson, M., Gerding, D. N., and McDonald, L. C.
- Abstract
Background: Efforts to prevent Clostridioides difficile infection continue to expand across the health care spectrum in the United States. Whether these efforts are reducing the national burden of C. difficile infection is unclear.Methods: The Emerging Infections Program identified cases of C. difficile infection (stool specimens positive for C. difficile in a person ≥1 year of age with no positive test in the previous 8 weeks) in 10 U.S. sites. We used case and census sampling weights to estimate the national burden of C. difficile infection, first recurrences, hospitalizations, and in-hospital deaths from 2011 through 2017. Health care-associated infections were defined as those with onset in a health care facility or associated with recent admission to a health care facility; all others were classified as community-associated infections. For trend analyses, we used weighted random-intercept models with negative binomial distribution and logistic-regression models to adjust for the higher sensitivity of nucleic acid amplification tests (NAATs) as compared with other test types.Results: The number of cases of C. difficile infection in the 10 U.S. sites was 15,461 in 2011 (10,177 health care-associated and 5284 community-associated cases) and 15,512 in 2017 (7973 health care-associated and 7539 community-associated cases). The estimated national burden of C. difficile infection was 476,400 cases (95% confidence interval [CI], 419,900 to 532,900) in 2011 and 462,100 cases (95% CI, 428,600 to 495,600) in 2017. With accounting for NAAT use, the adjusted estimate of the total burden of C. difficile infection decreased by 24% (95% CI, 6 to 36) from 2011 through 2017; the adjusted estimate of the national burden of health care-associated C. difficile infection decreased by 36% (95% CI, 24 to 54), whereas the adjusted estimate of the national burden of community-associated C. difficile infection was unchanged. The adjusted estimate of the burden of hospitalizations for C. difficile infection decreased by 24% (95% CI, 0 to 48), whereas the adjusted estimates of the burden of first recurrences and in-hospital deaths did not change significantly.Conclusions: The estimated national burden of C. difficile infection and associated hospitalizations decreased from 2011 through 2017, owing to a decline in health care-associated infections. (Funded by the Centers for Disease Control and Prevention.). [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
16. Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals.
- Author
-
Magill, S. S., O'Leary, E., Janelle, S. J., Thompson, D. L., Dumyati, G., Nadle, J., Wilson, L. E., Kainer, M. A., Lynfield, R., Greissman, S., Ray, S. M., Beldavs, Z., Gross, C., Bamberg, W., Sievers, M., Concannon, C., Buhr, N., Warnke, L., Maloney, M., and Ocampo, V.
- Abstract
Background: A point-prevalence survey that was conducted in the United States in 2011 showed that 4% of hospitalized patients had a health care-associated infection. We repeated the survey in 2015 to assess changes in the prevalence of health care-associated infections during a period of national attention to the prevention of such infections.Methods: At Emerging Infections Program sites in 10 states, we recruited up to 25 hospitals in each site area, prioritizing hospitals that had participated in the 2011 survey. Each hospital selected 1 day on which a random sample of patients was identified for assessment. Trained staff reviewed medical records using the 2011 definitions of health care-associated infections. We compared the percentages of patients with health care-associated infections and performed multivariable log-binomial regression modeling to evaluate the association of survey year with the risk of health care-associated infections.Results: In 2015, a total of 12,299 patients in 199 hospitals were surveyed, as compared with 11,282 patients in 183 hospitals in 2011. Fewer patients had health care-associated infections in 2015 (394 patients [3.2%; 95% confidence interval {CI}, 2.9 to 3.5]) than in 2011 (452 [4.0%; 95% CI, 3.7 to 4.4]) (P<0.001), largely owing to reductions in the prevalence of surgical-site and urinary tract infections. Pneumonia, gastrointestinal infections (most of which were due to Clostridium difficile [now Clostridioides difficile]), and surgical-site infections were the most common health care-associated infections. Patients' risk of having a health care-associated infection was 16% lower in 2015 than in 2011 (risk ratio, 0.84; 95% CI, 0.74 to 0.95; P=0.005), after adjustment for age, presence of devices, days from admission to survey, and status of being in a large hospital.Conclusions: The prevalence of health care-associated infections was lower in 2015 than in 2011. To continue to make progress in the prevention of such infections, prevention strategies against C. difficile infection and pneumonia should be augmented. (Funded by the Centers for Disease Control and Prevention.). [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
17. Carbapenem-resistant Acinetobacter baumannii complex in the United States-An epidemiological and molecular description of isolates collected through the Emerging Infections Program, 2019.
- Author
-
Bulens SN, Campbell D, McKay SL, Vlachos N, Burgin A, Burroughs M, Padila J, Grass JE, Jacob JT, Smith G, Muleta DB, Maloney M, Macierowski B, Wilson LE, Vaeth E, Lynfield R, O'Malley S, Snippes Vagnone PM, Dale J, Janelle SJ, Czaja CA, Johnson H, Phipps EC, Flores KG, Dumyati G, Tsay R, Beldavs ZG, Maureen Cassidy P, Hall A, Walters MS, Guh AY, Magill SS, and Lutgring JD
- Subjects
- Humans, United States epidemiology, Male, Middle Aged, Aged, Female, Adult, Aged, 80 and over, Whole Genome Sequencing, beta-Lactamases genetics, Communicable Diseases, Emerging microbiology, Communicable Diseases, Emerging epidemiology, Young Adult, Bacterial Proteins genetics, Acinetobacter baumannii drug effects, Acinetobacter baumannii genetics, Acinetobacter baumannii isolation & purification, Acinetobacter Infections epidemiology, Acinetobacter Infections microbiology, Carbapenems pharmacology, Anti-Bacterial Agents pharmacology, Microbial Sensitivity Tests
- Abstract
Background: Understanding the epidemiology of carbapenem-resistant A. baumannii complex (CRAB) and the patients impacted is an important step toward informing better infection prevention and control practices and improving public health response., Methods: Active, population-based surveillance was conducted for CRAB in 9 U.S. sites from January 1 to December 31, 2019. Medical records were reviewed, isolates were collected and characterized including antimicrobial susceptibility testing and whole genome sequencing., Results: Among 136 incident cases in 2019, 66 isolates were collected and characterized; 56.5% were from cases who were male, 54.5% were from persons of Black or African American race with non-Hispanic ethnicity, and the median age was 63.5 years. Most isolates, 77.2%, were isolated from urine, and 50.0% were collected in the outpatient setting; 72.7% of isolates harbored an acquired carbapenemase gene (aCP), predominantly bla
OXA-23 or blaOXA-24/40 ; however, an isolate with blaNDM was identified. The antimicrobial agent with the most in vitro activity was cefiderocol (96.9% of isolates were susceptible)., Conclusions: Our surveillance found that CRAB isolates in the U.S. commonly harbor an aCP, have an antimicrobial susceptibility profile that is defined as difficult-to-treat resistance, and epidemiologically are similar regardless of the presence of an aCP., (Published by Elsevier Inc.)- Published
- 2024
- Full Text
- View/download PDF
18. SHEA position statement on pandemic preparedness for policymakers: emerging infectious threats.
- Author
-
Hsu VP, Pergam SA, Shenoy ES, Banach DB, Jones Batshon L, Branch-Elliman W, Dumyati G, Haessler S, Jump RLP, Malani AN, Mathew TA, Murthy RK, and Weber DJ
- Subjects
- Humans, Communicable Diseases, Emerging prevention & control, Communicable Diseases, Emerging epidemiology, COVID-19 prevention & control, COVID-19 epidemiology, Disaster Planning organization & administration, Health Policy, Pandemic Preparedness, Pandemics prevention & control
- Published
- 2024
- Full Text
- View/download PDF
19. Society for Healthcare Epidemiology of America position statement on pandemic preparedness for policymakers: mitigating supply shortages.
- Author
-
Weber DJ, Malani AN, Shenoy ES, Banach DB, Batshon LJ, Branch-Elliman W, Dumyati G, Haessler S, Hsu VP, Jump RLP, Mathew TA, Murthy RK, and Pergam SA
- Subjects
- Humans, United States, Pandemics prevention & control, Infection Control methods, Infection Control organization & administration, SARS-CoV-2, Strategic Stockpile, Pandemic Preparedness, COVID-19 prevention & control, COVID-19 epidemiology, Personal Protective Equipment supply & distribution
- Abstract
The COVID-19 has had major direct (e.g., deaths) and indirect (e.g., social inequities) effects in the United States. While the public health response to the epidemic featured some important successes (e.g., universal masking ,and rapid development and approval of vaccines and therapeutics), there were systemic failures (e.g., inadequate public health infrastructure) that overshadowed these successes. Key deficiency in the U.S. response were shortages of personal protective equipment (PPE) and supply chain deficiencies. Recommendations are provided for mitigating supply shortages and supply chain failures in healthcare settings in future pandemics. Some key recommendations for preventing shortages of essential components of infection control and prevention include increasing the stockpile of PPE in the U.S. National Strategic Stockpile, increased transparency of the Stockpile, invoking the Defense Production Act at an early stage, and rapid review and authorization by FDA/EPA/OSHA of non-U.S. approved products. Recommendations are also provided for mitigating shortages of diagnostic testing, medications and medical equipment.
- Published
- 2024
- Full Text
- View/download PDF
20. SHEA position statement on pandemic preparedness for policymakers: building a strong and resilient healthcare workforce.
- Author
-
Banach DB, Mathew TA, Batshon LJ, Branch-Elliman W, Dumyati G, Haessler S, Hsu VP, Jump RLP, Malani AN, Murthy RK, Pergam SA, Shenoy ES, and Weber DJ
- Subjects
- Humans, United States epidemiology, Pandemics prevention & control, SARS-CoV-2, Infection Control methods, Infection Control organization & administration, Pandemic Preparedness, COVID-19 prevention & control, COVID-19 epidemiology, Health Workforce, Health Personnel
- Abstract
Throughout the COVID-19 pandemic, many areas in the United States experienced healthcare personnel (HCP) shortages tied to a variety of factors. Infection prevention programs, in particular, faced increasing workload demands with little opportunity to delegate tasks to others without specific infectious diseases or infection control expertise. Shortages of clinicians providing inpatient care to critically ill patients during the early phase of the pandemic were multifactorial, largely attributed to increasing demands on hospitals to provide care to patients hospitalized with COVID-19 and furloughs.
1 HCP shortages and challenges during later surges, including the Omicron variant-associated surges, were largely attributed to HCP infections and associated work restrictions during isolation periods and the need to care for family members, particularly children, with COVID-19. Additionally, the detrimental physical and mental health impact of COVID-19 on HCP has led to attrition, which further exacerbates shortages.2 Demands increased in post-acute and long-term care (PALTC) settings, which already faced critical staffing challenges difficulty with recruitment, and high rates of turnover. Although individual healthcare organizations and state and federal governments have taken actions to mitigate recurring shortages, additional work and innovation are needed to develop longer-term solutions to improve healthcare workforce resiliency. The critical role of those with specialized training in infection prevention, including healthcare epidemiologists, was well-demonstrated in pandemic preparedness and response. The COVID-19 pandemic underscored the need to support growth in these fields.3 This commentary outlines the need to develop the US healthcare workforce in preparation for future pandemics.- Published
- 2024
- Full Text
- View/download PDF
21. SHEA position statement on pandemic preparedness for policymakers: introduction and overview.
- Author
-
Hsu VP, Haessler S, Banach DB, Batshon LJ, Branch-Elliman W, Dumyati G, Jump RLP, Malani AN, Mathew TA, Murthy RK, Pergam SA, Shenoy ES, and Weber DJ
- Subjects
- Humans, SARS-CoV-2, United States epidemiology, Health Policy, Pandemic Preparedness, COVID-19 epidemiology, COVID-19 prevention & control, Pandemics prevention & control
- Abstract
Throughout history, pandemics and their aftereffects have spurred society to make substantial improvements in healthcare. After the Black Death in 14
th century Europe, changes were made to elevate standards of care and nutrition that resulted in improved life expectancy.1 The 1918 influenza pandemic spurred a movement that emphasized public health surveillance and detection of future outbreaks and eventually led to the creation of the World Health Organization Global Influenza Surveillance Network.2 In the present, the COVID-19 pandemic exposed many of the pre-existing problems within the US healthcare system, which included (1) a lack of capacity to manage a large influx of contagious patients while simultaneously maintaining routine and emergency care to non-COVID patients; (2) a "just in time" supply network that led to shortages and competition among hospitals, nursing homes, and other care sites for essential supplies; and (3) longstanding inequities in the distribution of healthcare and the healthcare workforce. The decades-long shift from domestic manufacturing to a reliance on global supply chains has compounded ongoing gaps in preparedness for supplies such as personal protective equipment and ventilators. Inequities in racial and socioeconomic outcomes highlighted during the pandemic have accelerated the call to focus on diversity, equity, and inclusion (DEI) within our communities. The pandemic accelerated cooperation between government entities and the healthcare system, resulting in swift implementation of mitigation measures, new therapies and vaccinations at unprecedented speeds, despite our fragmented healthcare delivery system and political divisions. Still, widespread misinformation or disinformation and political divisions contributed to eroded trust in the public health system and prevented an even uptake of mitigation measures, vaccines and therapeutics, impeding our ability to contain the spread of the virus in this country.3 Ultimately, the lessons of COVID-19 illustrate the need to better prepare for the next pandemic. Rising microbial resistance, emerging and re-emerging pathogens, increased globalization, an aging population, and climate change are all factors that increase the likelihood of another pandemic.4 .- Published
- 2024
- Full Text
- View/download PDF
22. SHEA position statement on pandemic preparedness for policymakers: pandemic data collection, maintenance, and release.
- Author
-
Branch-Elliman W, Banach DB, Batshon LJ, Dumyati G, Haessler S, Hsu VP, Jump RLP, Malani AN, Mathew TA, Murthy RK, Pergam SA, Shenoy ES, and Weber DJ
- Subjects
- Humans, United States, COVID-19 prevention & control, COVID-19 epidemiology, Societies, Medical, Information Dissemination methods, Pandemic Preparedness, Pandemics prevention & control, Data Collection methods, Data Collection standards
- Abstract
The Society for Healthcare Epidemiology in America (SHEA) strongly supports modernization of data collection processes and the creation of publicly available data repositories that include a wide variety of data elements and mechanisms for securely storing both cleaned and uncleaned data sets that can be curated as clinical and research needs arise. These elements can be used for clinical research and quality monitoring and to evaluate the impacts of different policies on different outcomes. Achieving these goals will require dedicated, sustained and long-term funding to support data science teams and the creation of central data repositories that include data sets that can be "linked" via a variety of different mechanisms and also data sets that include institutional and state and local policies and procedures. A team-based approach to data science is strongly encouraged and supported to achieve the goal of a sustainable, adaptable national shared data resource.
- Published
- 2024
- Full Text
- View/download PDF
23. SHEA position statement on pandemic preparedness for policymakers: the role of healthcare epidemiologists in communicating during infectious diseases outbreaks.
- Author
-
Shenoy ES, Banach DB, Batshon LJ, Branch-Elliman W, Dumyati G, Haessler S, Hsu VP, Jump RLP, Malani AN, Mathew TA, Murthy RK, Pergam SA, Seeger MW, and Weber DJ
- Subjects
- Humans, Disease Outbreaks prevention & control, Communication, Pandemic Preparedness, Epidemiologists, Pandemics prevention & control
- Published
- 2024
- Full Text
- View/download PDF
24. Carbapenem-Resistant and Extended-Spectrum β-Lactamase-Producing Enterobacterales in Children, United States, 2016-2020.
- Author
-
Grome HN, Grass JE, Duffy N, Bulens SN, Ansari U, Campbell D, Lutgring JD, Gargis AS, Masters T, Kent AG, McKay SL, Smith G, Wilson LE, Vaeth E, Evenson B, Dumyati G, Tsay R, Phipps E, Flores K, Wilson CD, Czaja CA, Johnston H, Janelle SJ, Lynfield R, O'Malley S, Vagnone PS, Maloney M, Nadle J, and Guh AY
- Subjects
- Humans, Child, United States epidemiology, Child, Preschool, Microbial Sensitivity Tests, Enterobacteriaceae drug effects, Enterobacteriaceae genetics, Enterobacteriaceae enzymology, Infant, History, 21st Century, Adolescent, Male, beta-Lactamases genetics, Enterobacteriaceae Infections epidemiology, Enterobacteriaceae Infections microbiology, Anti-Bacterial Agents pharmacology, Carbapenems pharmacology, Carbapenem-Resistant Enterobacteriaceae genetics, Carbapenem-Resistant Enterobacteriaceae isolation & purification, Carbapenem-Resistant Enterobacteriaceae drug effects
- Published
- 2024
- Full Text
- View/download PDF
25. Characteristics of healthcare personnel with SARS-CoV-2 infection: 10 emerging infections program sites in the United States, April 2020-December 2021.
- Author
-
Chea N, Eure T, Alkis Ramirez R, Zlotorzynska M, Blazek GT, Nadle J, Lee J, Czaja CA, Johnston H, Barter D, Kellogg M, Emanuel C, Meek J, Brackney M, Carswell S, Thomas S, Fridkin SK, Wilson LE, Perlmutter R, Marceaux-Galli K, Fell A, Lovett S, Lim S, Lynfield R, Shrum Davis S, Phipps EC, Sievers M, Dumyati G, Myers C, Hurley C, Licherdell E, Pierce R, Ocampo VLS, Hall EW, Wilson C, Adre C, Kirtz E, Markus TM, Billings K, Plumb ID, Abedi GR, James-Gist J, Magill SS, and Grigg CT
- Abstract
Background: Understanding characteristics of healthcare personnel (HCP) with SARS-CoV-2 infection supports the development and prioritization of interventions to protect this important workforce. We report detailed characteristics of HCP who tested positive for SARS-CoV-2 from April 20, 2020 through December 31, 2021., Methods: CDC collaborated with Emerging Infections Program sites in 10 states to interview HCP with SARS-CoV-2 infection (case-HCP) about their demographics, underlying medical conditions, healthcare roles, exposures, personal protective equipment (PPE) use, and COVID-19 vaccination status. We grouped case-HCP by healthcare role. To describe residential social vulnerability, we merged geocoded HCP residential addresses with CDC/ATSDR Social Vulnerability Index (SVI) values at the census tract level. We defined highest and lowest SVI quartiles as high and low social vulnerability, respectively., Results: Our analysis included 7,531 case-HCP. Most case-HCP with roles as certified nursing assistant (CNA) (444, 61.3%), medical assistant (252, 65.3%), or home healthcare worker (HHW) (225, 59.5%) reported their race and ethnicity as either non-Hispanic Black or Hispanic. More than one third of HHWs (166, 45.2%), CNAs (283, 41.7%), and medical assistants (138, 37.9%) reported a residential address in the high social vulnerability category. The proportion of case-HCP who reported using recommended PPE at all times when caring for patients with COVID-19 was lowest among HHWs compared with other roles., Conclusions: To mitigate SARS-CoV-2 infection risk in healthcare settings, infection prevention, and control interventions should be specific to HCP roles and educational backgrounds. Additional interventions are needed to address high social vulnerability among HHWs, CNAs, and medical assistants.
- Published
- 2024
- Full Text
- View/download PDF
26. Sociodemographic and Occupational Characteristics Associated with Early and Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
- Author
-
Russ S, Myers C, Licherdell E, Bowden A, Chinchilli E, Dahhan R, Van Wijngaarden E, Plumb ID, and Dumyati G
- Subjects
- Humans, New York, Retrospective Studies, Cognition, Vaccination, COVID-19 Vaccines, COVID-19 prevention & control
- Abstract
Objective: Identify characteristics of healthcare personnel (HCP) who did not have timely initiation of the COVID-19 primary series, as well as HCP who did not receive a booster vaccine., Methods: Characteristics of HCP enrolled in a COVID-19 vaccine effectiveness study between 12/28/2020-12/01/2022 were compared by timing of receipt of 1st mRNA dose, and by receipt of a booster dose. Data for this retrospective cohort analysis came from HCP working at a large healthcare system in Monroe County, New York, and included standardized questionnaires and verified vaccination status. HCP were categorized by whether they received their 1stmRNA COVID-19 vaccine between 12/14/2020-03/30/2021 (earlier) or 04/01/2021-09/28/2021 (later) based on timing of local vaccine eligibility and mandates, and by whether they received a 3rdmRNA booster dose by 12/01/22. Logistic regression models were run to identify characteristics of HCP who had later 1stdose receipt or did not receive a booster., Results: 3,375 HCP were enrolled. Of these, 86.8 % had early initiation of their 1stCOVID-19 vaccine, and 85.0 % received a booster dose. Low education, low household income, younger age (<50), non-White race and public health insurance were all significant predictors of later receipt of 1stdose and lack of uptake of a booster. However, advanced professional role was only found to be a significant predictor of early 1stdose receipt., Conclusions: Continual monitoring of COVID-19 vaccine uptake among HCP to identify those less likely to receive new booster doses will be crucial to support targeted vaccine campaigns in this important population., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
- Author
-
Plumb ID, Briggs Hagen M, Wiegand R, Dumyati G, Myers C, Harland KK, Krishnadasan A, James Gist J, Abedi G, Fleming-Dutra KE, Chea N, Lee JE, Kellogg M, Edmundson A, Britton A, Wilson LE, Lovett SA, Ocampo V, Markus TM, Smithline HA, Hou PC, Lee LC, Mower W, Rwamwejo F, Steele MT, Lim SC, Schrading WA, Chinnock B, Beiser DG, Faine B, Haran JP, Nandi U, Chipman AK, LoVecchio F, Eucker S, Femling J, Fuller M, Rothman RE, Curlin ME, Talan DA, and Mohr NM
- Subjects
- Humans, Infant, Newborn, COVID-19 Vaccines, Vaccines, Combined, mRNA Vaccines, Case-Control Studies, SARS-CoV-2, RNA, Messenger, Delivery of Health Care, COVID-19 prevention & control
- Abstract
Background: Bivalent mRNA vaccines were recommended since September 2022. However, coverage with a recent vaccine dose has been limited, and there are few robust estimates of bivalent VE against symptomatic SARS-CoV-2 infection (COVID-19). We estimated VE of a bivalent mRNA vaccine dose against COVID-19 among eligible U.S. healthcare personnel who had previously received monovalent mRNA vaccine doses., Methods: We conducted a case-control study in 22 U.S. states, and enrolled healthcare personnel with COVID-19 (case-participants) or without COVID-19 (control-participants) during September 2022-May 2023. Participants were considered eligible for a bivalent mRNA dose if they had received 2-4 monovalent (ancestral-strain) mRNA vaccine doses, and were ≥67 days after the most recent vaccine dose. We estimated VE of a bivalent mRNA dose using conditional logistic regression, accounting for matching by region and four-week calendar period. We adjusted estimates for age group, sex, race and ethnicity, educational level, underlying health conditions, community COVID-19 exposure, prior SARS-CoV-2 infection, and days since the last monovalent mRNA dose., Results: Among 3,647 healthcare personnel, 1,528 were included as case-participants and 2,119 as control-participants. Participants received their last monovalent mRNA dose a median of 404 days previously; 1,234 (33.8%) also received a bivalent mRNA dose a median of 93 days previously. Overall, VE of a bivalent dose was 34.1% (95% CI, 22.6%-43.9%) against COVID-19 and was similar by product, days since last monovalent dose, number of prior doses, age group, and presence of underlying health conditions. However, VE declined from 54.8% (95% CI, 40.7%-65.6%) after 7-59 days to 21.6% (95% CI 5.6%-34.9%) after ≥60 days., Conclusions: Bivalent mRNA COVID-19 vaccines initially conferred approximately 55% protection against COVID-19 among U.S. healthcare personnel. However, protection waned after two months. These findings indicate moderate initial protection against symptomatic SARS-CoV-2 infection by remaining up-to-date with COVID-19 vaccines., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Monica Brackney owned stock in Moderna from November 2022–April 2023 stock as part of portfolio managed by Parametric Investments Portfolio LLC. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.]., (Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
28. Residential social vulnerability among healthcare personnel with and without severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in Five US states, May-December 2020.
- Author
-
Zlotorzynska M, Chea N, Eure T, Alkis Ramirez R, Blazek GT, Czaja CA, Johnston H, Barter D, Kellogg M, Emanuel C, Lynfield R, Fell A, Lim S, Lovett S, Phipps EC, Shrum Davis S, Sievers M, Dumyati G, Concannon C, Myers C, McCullough K, Woods A, Hurley C, Licherdell E, Pierce R, Ocampo VLS, Hall E, Magill SS, and Grigg CT
- Subjects
- Humans, SARS-CoV-2, Case-Control Studies, Social Vulnerability, Delivery of Health Care, COVID-19 epidemiology
- Abstract
Objective: To characterize residential social vulnerability among healthcare personnel (HCP) and evaluate its association with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection., Design: Case-control study., Setting: This study analyzed data collected in May-December 2020 through sentinel and population-based surveillance in healthcare facilities in Colorado, Minnesota, New Mexico, New York, and Oregon., Participants: Data from 2,168 HCP (1,571 cases and 597 controls from the same facilities) were analyzed., Methods: HCP residential addresses were linked to the social vulnerability index (SVI) at the census tract level, which represents a ranking of community vulnerability to emergencies based on 15 US Census variables. The primary outcome was SARS-CoV-2 infection, confirmed by positive antigen or real-time reverse-transcriptase- polymerase chain reaction (RT-PCR) test on nasopharyngeal swab. Significant differences by SVI in participant characteristics were assessed using the Fisher exact test. Adjusted odds ratios (aOR) with 95% confidence intervals (CIs) for associations between case status and SVI, controlling for HCP role and patient care activities, were estimated using logistic regression., Results: Significantly higher proportions of certified nursing assistants (48.0%) and medical assistants (44.1%) resided in high SVI census tracts, compared to registered nurses (15.9%) and physicians (11.6%). HCP cases were more likely than controls to live in high SVI census tracts (aOR, 1.76; 95% CI, 1.37-2.26)., Conclusions: These findings suggest that residing in more socially vulnerable census tracts may be associated with SARS-CoV-2 infection risk among HCP and that residential vulnerability differs by HCP role. Efforts to safeguard the US healthcare workforce and advance health equity should address the social determinants that drive racial, ethnic, and socioeconomic health disparities.
- Published
- 2024
- Full Text
- View/download PDF
29. Trends in Incidence of Carbapenem-Resistant Enterobacterales in 7 US Sites, 2016─2020.
- Author
-
Duffy N, Li R, Czaja CA, Johnston H, Janelle SJ, Jacob JT, Smith G, Wilson LE, Vaeth E, Lynfield R, O'Malley S, Vagnone PS, Dumyati G, Tsay R, Bulens SN, Grass JE, Pierce R, Cassidy PM, Hertzel H, Wilson C, Muleta D, Taylor J, and Guh AY
- Abstract
Background: We described changes in 2016─2020 carbapenem-resistant Enterobacterales (CRE) incidence rates in 7 US sites that conduct population-based CRE surveillance., Methods: An incident CRE case was defined as the first isolation of Escherichia coli , Klebsiella spp., or Enterobacter spp. resistant to ≥1 carbapenem from a sterile site or urine in a surveillance area resident in a 30-day period. We reviewed medical records and classified cases as hospital-onset (HO), healthcare-associated community-onset (HACO), or community-associated (CA) CRE based on healthcare exposures and location of disease onset. We calculated incidence rates using census data. We used Poisson mixed effects regression models to perform 2016─2020 trend analyses, adjusting for sex, race/ethnicity, and age. We compared adjusted incidence rates between 2016 and subsequent years using incidence rate ratios (RRs) and 95% confidence intervals (CIs)., Results: Of 4996 CRE cases, 62% were HACO, 21% CA, and 14% HO. The crude CRE incidence rate per 100 000 was 7.51 in 2016 and 6.08 in 2020 and was highest for HACO, followed by CA and HO. From 2016 to 2020, the adjusted overall CRE incidence rate decreased by 24% (RR, 0.76 [95% CI, .70-.83]). Significant decreases in incidence rates in 2020 were seen for HACO (RR, 0.75 [95% CI, .67-.84]) and CA (0.75 [.61-.92]) but not for HO CRE., Conclusions: Adjusted CRE incidence rates declined from 2016 to 2020, but changes over time varied by epidemiologic class. Continued surveillance and effective control strategies are needed to prevent CRE in all settings., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.)
- Published
- 2023
- Full Text
- View/download PDF
30. Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021-July 2022.
- Author
-
Plumb ID, Mohr NM, Hagen M, Wiegand R, Dumyati G, Harland KK, Krishnadasan A, Gist JJ, Abedi G, Fleming-Dutra KE, Chea N, Lee J, Barter D, Brackney M, Fridkin SK, Wilson LE, Lovett SA, Ocampo V, Phipps EC, Marcus TM, Smithline HA, Hou PC, Lee LC, Moran GJ, Krebs E, Steele MT, Lim SC, Schrading WA, Chinnock B, Beiser DG, Faine B, Haran JP, Nandi U, Chipman AK, LoVecchio F, Talan DA, and Pilishvili T
- Abstract
Background: Protection against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019 [COVID-19]) can limit transmission and the risk of post-COVID conditions, and is particularly important among healthcare personnel. However, lower vaccine effectiveness (VE) has been reported since predominance of the Omicron SARS-CoV-2 variant., Methods: We evaluated the VE of a monovalent messenger RNA (mRNA) booster dose against COVID-19 from October 2021 to June 2022 among US healthcare personnel. After matching case-participants with COVID-19 to control-participants by 2-week period and site, we used conditional logistic regression to estimate the VE of a booster dose compared with completing only 2 mRNA doses >150 days previously, adjusted for multiple covariates., Results: Among 3279 case-participants and 3998 control-participants who had completed 2 mRNA doses, we estimated that the VE of a booster dose against COVID-19 declined from 86% (95% confidence interval, 81%-90%) during Delta predominance to 65% (58%-70%) during Omicron predominance. During Omicron predominance, VE declined from 73% (95% confidence interval, 67%-79%) 14-60 days after the booster dose, to 32% (4%-52%) ≥120 days after a booster dose. We found that VE was similar by age group, presence of underlying health conditions, and pregnancy status on the test date, as well as among immunocompromised participants., Conclusions: A booster dose conferred substantial protection against COVID-19 among healthcare personnel. However, VE was lower during Omicron predominance, and waning effectiveness was observed 4 months after booster dose receipt during this period. Our findings support recommendations to stay up to date on recommended doses of COVID-19 vaccines for all those eligible., Competing Interests: Potential conflicts of interest. M. B. owned stock in Moderna from November 2022 to April 2023, as part of portfolio managed by Parametric Investments Portfolio. All other authors report no potential conflicts., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.)
- Published
- 2023
- Full Text
- View/download PDF
31. Epidemiology of Pulmonary and Extrapulmonary Nontuberculous Mycobacteria Infections at 4 US Emerging Infections Program Sites: A 6-Month Pilot.
- Author
-
Grigg C, Jackson KA, Barter D, Czaja CA, Johnston H, Lynfield R, Vagnone PS, Tourdot L, Spina N, Dumyati G, Cassidy PM, Pierce R, Henkle E, Prevots DR, Salfinger M, Winthrop KL, Toney NC, and Magill SS
- Subjects
- Humans, Female, Male, Nontuberculous Mycobacteria, Lung microbiology, Oregon epidemiology, Mycobacterium Infections, Nontuberculous microbiology, Lung Diseases epidemiology, Lung Diseases microbiology
- Abstract
Background: Nontuberculous mycobacteria (NTM) cause pulmonary (PNTM) and extrapulmonary (ENTM) disease. Infections are difficult to diagnose and treat, and exposures occur in healthcare and community settings. In the United States, NTM epidemiology has been described largely through analyses of microbiology data from health departments, electronic health records, and administrative data. We describe findings from a multisite pilot of active, laboratory- and population-based NTM surveillance., Methods: The Centers for Disease Control and Prevention's Emerging Infections Program conducted NTM surveillance at 4 sites (Colorado, 5 counties; Minnesota, 2 counties; New York, 2 counties; and Oregon, 3 counties [PNTM] and statewide [ENTM]) from 1 October 2019 through 31 March 2020. PNTM cases were defined using published microbiologic criteria. ENTM cases required NTM isolation from a nonpulmonary specimen, excluding stool and rectal swabs. Patient data were collected via medical record review., Results: Overall, 299 NTM cases were reported (PNTM: 231, 77%); Mycobacterium avium complex was the most common species group. Annualized prevalence was 7.5/100 000 population (PNTM: 6.1/100 000; ENTM: 1.4/100 000). Most patients had signs or symptoms in the 14 days before positive specimen collection (ENTM: 62, 91.2%; PNTM: 201, 87.0%). Of PNTM cases, 145 (62.8%) were female and 168 (72.7%) had underlying chronic lung disease. Among ENTM cases, 29 (42.6%) were female, 21 (30.9%) did not have documented underlying conditions, and 26 (38.2%) had infection at the site of a medical device or procedure., Conclusions: Active, population-based NTM surveillance will provide data for monitoring the burden of disease and characterize affected populations to inform interventions., Competing Interests: Potential conflicts of interest. EIP site coauthors' institutions received funding from the CDC. E. H. reports receipt of consulting fees and serving on advisory boards for AN2 Therapeutics and the MannKind Corporation. K. L. W. reports receipt of grants or contracts and consulting fees from Insmed, Paratek, Red Hill Biopharma, AN2 Therapeutics, Renovion, and Spero and participation on a data and safety monitoring board or advisory board for Red Hill Biopharma. R. L. reports service on the program committee for IDWeek and receipt of travel support for conference planning and for the conference; service as associate editor for the American Academy of Pediatrics (AAP) Red Book; receipt of fees for editorial work that were donated to the Minnesota Department of Health; receipt of support to attend the AAP Committee on Infectious Disease meetings; service on the Council of State and Territorial Epidemiologists (CSTE) Executive Board and receipt of travel support to attend CSTE meetings; and service on the board of the National Foundation of Infectious Disease (NFID) and receipt of travel support to attend NFID meetings. D. R. P. reports support for this work and support for attending meetings and/or travel from the Division of Intramural Research, NIAID, NIH. All remaining authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.)
- Published
- 2023
- Full Text
- View/download PDF
32. Determinates of Clostridioides difficile infection (CDI) testing practices among inpatients with diarrhea at selected acute-care hospitals in Rochester, New York, and Atlanta, Georgia, 2020-2021.
- Author
-
Fridkin SK, Onwubiko UN, Dube W, Robichaux C, Traenkner J, Goodenough D, Angulo FJ, Zamparo JM, Gonzalez E, Khanna S, Myers C, and Dumyati G
- Subjects
- Humans, Inpatients, Georgia epidemiology, New York epidemiology, Hospitals, Diarrhea diagnosis, Diarrhea epidemiology, Surveys and Questionnaires, Clostridioides difficile, Clostridium Infections diagnosis, Clostridium Infections epidemiology, Cross Infection diagnosis, Cross Infection epidemiology
- Abstract
Objective: We evaluated the impact of test-order frequency per diarrheal episodes on Clostridioides difficile infection (CDI) incidence estimates in a sample of hospitals at 2 CDC Emerging Infections Program (EIP) sites., Design: Observational survey., Setting: Inpatients at 5 acute-care hospitals in Rochester, New York, and Atlanta, Georgia, during two 10-workday periods in 2020 and 2021., Outcomes: We calculated diarrhea incidence, testing frequency, and CDI positivity (defined as any positive NAAT test) across strata. Predictors of CDI testing and positivity were assessed using modified Poisson regression. Population estimates of incidence using modified Emerging Infections Program methodology were compared between sites using the Mantel-Hanzel summary rate ratio., Results: Surveillance of 38,365 patient days identified 860 diarrhea cases from 107 patient-care units mapped to 26 unique NHSN defined location types. Incidence of diarrhea was 22.4 of 1,000 patient days (medians, 25.8 for Rochester and 16.2 for Atlanta; P < .01). Similar proportions of diarrhea cases were hospital onset (66%) at both sites. Overall, 35% of patients with diarrhea were tested for CDI, but this differed by site: 21% in Rochester and 49% in Atlanta ( P < .01). Regression models identified location type (ie, oncology or critical care) and laxative use predictive of CDI test ordering. Adjusting for these factors, CDI testing was 49% less likely in Rochester than Atlanta (adjusted rate ratio, 0.51; 95% confidence interval [CI], 0.40-0.63). Population estimates in Rochester had a 38% lower incidence of CDI than Atlanta (summary rate ratio, 0.62; 95% CI, 0.54-0.71)., Conclusion: Accounting for patient-specific factors that influence CDI test ordering, differences in testing practices between sites remain and likely contribute to regional differences in surveillance estimates.
- Published
- 2023
- Full Text
- View/download PDF
33. Assessing Pathogen Transmission Opportunities: Variation in Nursing Home Staff-Resident Interactions.
- Author
-
Nelson Chang NC, Leecaster M, Fridkin S, Dube W, Katz M, Polgreen P, Roghmann MC, Khader K, Li L, Dumyati G, Tsay R, Lynfield R, Mahoehney JP, Nadle J, Hutson J, Pierce R, Zhang A, Wilson C, Haroldsen C, Mulvey D, Reddy SC, Stone ND, Slayton RB, Thompson ND, Stratford K, Samore M, and Visnovsky LD
- Subjects
- Humans, Cross-Sectional Studies, Health Personnel, Anti-Bacterial Agents, Nursing Homes, Infection Control
- Abstract
Objectives: The Centers for Disease Control and Prevention (CDC) recommends implementing Enhanced Barrier Precautions (EBP) for all nursing home (NH) residents known to be colonized with targeted multidrug-resistant organisms (MDROs), wounds, or medical devices. Differences in health care personnel (HCP) and resident interactions between units may affect risk of acquiring and transmitting MDROs, affecting EBP implementation. We studied HCP-resident interactions across a variety of NHs to characterize MDRO transmission opportunities., Design: 2 cross-sectional visits., Setting and Participants: Four CDC Epicenter sites and CDC Emerging Infection Program sites in 7 states recruited NHs with a mix of unit care types (≥30 beds or ≥2 units). HCP were observed providing resident care., Methods: Room-based observations and HCP interviews assessed HCP-resident interactions, care type provided, and equipment use. Observations and interviews were conducted for 7-8 hours in 3-6-month intervals per unit. Chart reviews collected deidentified resident demographics and MDRO risk factors (eg, indwelling devices, pressure injuries, and antibiotic use)., Results: We recruited 25 NHs (49 units) with no loss to follow-up, conducted 2540 room-based observations (total duration: 405 hours), and 924 HCP interviews. HCP averaged 2.5 interactions per resident per hour (long-term care units) to 3.4 per resident per hour (ventilator care units). Nurses provided care to more residents (n = 12) than certified nursing assistants (CNAs) and respiratory therapists (RTs) (CNA: 9.8 and RT: 9) but nurses performed significantly fewer task types per interaction compared to CNAs (incidence rate ratio (IRR): 0.61, P < .05). Short-stay (IRR: 0.89) and ventilator-capable (IRR: 0.94) units had less varied care compared with long-term care units (P < .05), although HCP visited residents in these units at similar rates., Conclusions and Implications: Resident-HCP interaction rates are similar across NH unit types, differing primarily in types of care provided. Current and future interventions such as EBP, care bundling, or targeted infection prevention education should consider unit-specific HCP-resident interaction patterns., (Copyright © 2023 AMDA – The Society for Post-Acute and Long-Term Care Medicine. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
34. Vital Signs: Health Disparities in Hemodialysis-Associated Staphylococcus aureus Bloodstream Infections - United States, 2017-2020.
- Author
-
Rha B, See I, Dunham L, Kutty PK, Moccia L, Apata IW, Ahern J, Jung S, Li R, Nadle J, Petit S, Ray SM, Harrison LH, Bernu C, Lynfield R, Dumyati G, Tracy M, Schaffner W, Ham DC, Magill SS, O'Leary EN, Bell J, Srinivasan A, McDonald LC, Edwards JR, and Novosad S
- Subjects
- Adult, Humans, United States epidemiology, Staphylococcus aureus, Renal Dialysis adverse effects, Ethnicity, Vital Signs, Healthcare Disparities, Kidney Failure, Chronic therapy, Kidney Failure, Chronic etiology, Sepsis etiology
- Abstract
Introduction: Racial and ethnic minorities are disproportionately affected by end-stage kidney disease (ESKD). ESKD patients on dialysis are at increased risk for Staphylococcus aureus bloodstream infections, but racial, ethnic, and socioeconomic disparities associated with this outcome are not well described., Methods: Surveillance data from the 2020 National Healthcare Safety Network (NHSN) and the 2017-2020 Emerging Infections Program (EIP) were used to describe bloodstream infections among patients on hemodialysis (hemodialysis patients) and were linked to population-based data sources (CDC/Agency for Toxic Substances and Disease Registry [ATSDR] Social Vulnerability Index [SVI], United States Renal Data System [USRDS], and U.S. Census Bureau) to examine associations with race, ethnicity, and social determinants of health., Results: In 2020, 4,840 dialysis facilities reported 14,822 bloodstream infections to NHSN; 34.2% were attributable to S. aureus . Among seven EIP sites, the S. aureus bloodstream infection rate during 2017-2020 was 100 times higher among hemodialysis patients (4,248 of 100,000 person-years) than among adults not on hemodialysis (42 of 100,000 person-years). Unadjusted S. aureus bloodstream infection rates were highest among non-Hispanic Black or African American (Black) and Hispanic or Latino (Hispanic) hemodialysis patients. Vascular access via central venous catheter was strongly associated with S. aureus bloodstream infections (NHSN: adjusted rate ratio [aRR] = 6.2; 95% CI = 5.7-6.7 versus fistula; EIP: aRR = 4.3; 95% CI = 3.9-4.8 versus fistula or graft). Adjusting for EIP site of residence, sex, and vascular access type, S. aureus bloodstream infection risk in EIP was highest in Hispanic patients (aRR = 1.4; 95% CI = 1.2-1.7 versus non-Hispanic White [White] patients), and patients aged 18-49 years (aRR = 1.7; 95% CI = 1.5-1.9 versus patients aged ≥65 years). Areas with higher poverty levels, crowding, and lower education levels accounted for disproportionately higher proportions of hemodialysis-associated S. aureus bloodstream infections., Conclusions and Implications for Public Health Practice: Disparities exist in hemodialysis-associated S. aureus infections. Health care providers and public health professionals should prioritize prevention and optimized treatment of ESKD, identify and address barriers to lower-risk vascular access placement, and implement established best practices to prevent bloodstream infections., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
35. Epidemiology of Sepsis in US Children and Young Adults.
- Author
-
Magill SS, Sapiano MRP, Gokhale R, Nadle J, Johnston H, Brousseau G, Maloney M, Ray SM, Wilson LE, Perlmutter R, Lynfield R, DeSilva M, Sievers M, Irizarry L, Dumyati G, Pierce R, Zhang A, Kainer M, Fiore AE, Dantes R, and Epstein L
- Abstract
Background: Most multicenter studies of US pediatric sepsis epidemiology use administrative data or focus on pediatric intensive care units. We conducted a detailed medical record review to describe sepsis epidemiology in children and young adults., Methods: In a convenience sample of hospitals in 10 states, patients aged 30 days-21 years, discharged during 1 October 2014-30 September 2015, with explicit diagnosis codes for severe sepsis or septic shock, were included. Medical records were reviewed for patients with documentation of sepsis, septic shock, or similar terms. We analyzed overall and age group-specific patient characteristics., Results: Of 736 patients in 26 hospitals, 442 (60.1%) had underlying conditions. Most patients (613 [83.3%]) had community-onset sepsis, although most community-onset sepsis was healthcare associated (344 [56.1%]). Two hundred forty-one patients (32.7%) had outpatient visits 1-7 days before sepsis hospitalization, of whom 125 (51.9%) received antimicrobials ≤30 days before sepsis hospitalization. Age group-related differences included common underlying conditions (<5 years: prematurity vs 5-12 years: chronic pulmonary disease vs 13-21 years: chronic immunocompromise); medical device presence ≤30 days before sepsis hospitalization (1-4 years: 46.9% vs 30 days-11 months: 23.3%); percentage with hospital-onset sepsis (<5 years: 19.6% vs ≥5 years: 12.0%); and percentage with sepsis-associated pathogens (30 days-11 months: 65.6% vs 13-21 years: 49.3%)., Conclusions: Our data suggest potential opportunities to raise sepsis awareness among outpatient providers to facilitate prevention, early recognition, and intervention in some patients. Consideration of age-specific differences may be important as approaches are developed to improve sepsis prevention, risk prediction, recognition, and management., Competing Interests: Potential conflicts of interest. G. D.: personal fees from Seres Therapeutics. R. L.: payment for serving as Associate Editor of the American Academy of Pediatrics Red Book (donated to the Minnesota Department of Health); support for attending meetings and/or travel as a member of the IDWeek Program Committee; support for attending meetings and/or travel as an Executive Board Member of the Council for State and Territorial Epidemiologists; support for attending meetings and/or travel as an Executive Board Member of the National Foundation for Infectious Diseases; and support for attending meetings and/or travel from the American Academy of Pediatrics, Committee on Infectious Diseases. M. K.: reimbursement for time participating in the CSF Seqirus Asia-Pacific Advisory Council; and compensation and travel support for service on the board of the Infectious Disease Consulting Corporation. M. M.: recipient of Public Health Scholarship support for meeting attendance/travel to the Society for Healthcare Epidemiology of America 2019 spring meeting. All authors affiliated with EIP sites report support for their institutions from the Centers for Disease Control and Prevention. All other authors report no potential conflicts., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.)
- Published
- 2023
- Full Text
- View/download PDF
36. Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 Update.
- Author
-
Kociolek LK, Gerding DN, Carrico R, Carling P, Donskey CJ, Dumyati G, Kuhar DT, Loo VG, Maragakis LL, Pogorzelska-Maziarz M, Sandora TJ, Weber DJ, Yokoe D, and Dubberke ER
- Subjects
- Humans, Hospitals, Clostridioides difficile, Clostridium Infections
- Published
- 2023
- Full Text
- View/download PDF
37. Health Care-Associated Infections in Older Adults: Epidemiology and Prevention.
- Author
-
Tesini BL and Dumyati G
- Subjects
- Humans, Aged, Infection Control, Health Facilities, Delivery of Health Care, Catheter-Related Infections prevention & control, Cross Infection epidemiology, Cross Infection prevention & control, Urinary Tract Infections epidemiology
- Abstract
Health care-associated infections (HAIs) are a global public health threat, which disproportionately impact older adults. Host factors including aging-related changes, comorbidities, and geriatric syndromes, such as dementia and frailty, predispose older individuals to infection. The HAI risks from medical interventions such as device use, antibiotic use, and lapses in infection control follow older adults as they transfer among a network of interrelated acute and long-term care facilities. Long-term care facilities are caring for patients with increasingly complex needs, and the home-like communal environment of long-term care facilities creates distinct infection prevention challenges., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
38. Carbapenem-Resistant enterobacterales in individuals with and without health care risk factors -Emerging infections program, United States, 2012-2015.
- Author
-
Bulens SN, Reses HE, Ansari UA, Grass JE, Carmon C, Albrecht V, Lawsin A, McAllister G, Daniels J, Lee YK, Yi S, See I, Jacob JT, Bower CW, Wilson L, Vaeth E, Lynfield R, Vagnone PS, Shaw KM, Dumyati G, Tsay R, Phipps EC, Bamberg W, Janelle SJ, Beldavs ZG, Cassidy PM, Kainer M, Muleta D, Mounsey JT, Laufer-Halpin A, Karlsson M, Lutgring JD, and Walters MS
- Subjects
- Female, United States epidemiology, Humans, Enterobacteriaceae, beta-Lactamases genetics, Health Facilities, Risk Factors, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Microbial Sensitivity Tests, Carbapenems pharmacology, Enterobacteriaceae Infections epidemiology, Enterobacteriaceae Infections drug therapy
- Abstract
Background: Carbapenem-resistant Enterobacterales (CRE) are usually healthcare-associated but are also emerging in the community., Methods: Active, population-based surveillance was conducted to identify case-patients with cultures positive for Enterobacterales not susceptible to a carbapenem (excluding ertapenem) and resistant to all third-generation cephalosporins tested at 8 US sites from January 2012 to December 2015. Medical records were used to classify cases as health care-associated, or as community-associated (CA) if a patient had no known health care risk factors and a culture was collected <3 days after hospital admission. Enterobacterales isolates from selected cases were submitted to CDC for whole genome sequencing., Results: We identified 1499 CRE cases in 1194 case-patients; 149 cases (10%) in 139 case-patients were CA. The incidence of CRE cases per 100,000 population was 2.96 (95% CI: 2.81, 3.11) overall and 0.29 (95% CI: 0.25, 0.35) for CA-CRE. Most CA-CRE cases were in White persons (73%), females (84%) and identified from urine cultures (98%). Among the 12 sequenced CA-CRE isolates, 5 (42%) harbored a carbapenemase gene., Conclusions: Ten percent of CRE cases were CA; some isolates from CA-CRE cases harbored carbapenemase genes. Continued CRE surveillance in the community is critical to monitor emergence outside of traditional health care settings., (Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
39. Epidemiology of extended-spectrum β-lactamase-producing Enterobacterales in five US sites participating in the Emerging Infections Program, 2017.
- Author
-
Duffy N, Karlsson M, Reses HE, Campbell D, Daniels J, Stanton RA, Janelle SJ, Schutz K, Bamberg W, Rebolledo PA, Bower C, Blakney R, Jacob JT, Phipps EC, Flores KG, Dumyati G, Kopin H, Tsay R, Kainer MA, Muleta D, Byrd-Warner B, Grass JE, Lutgring JD, Rasheed JK, Elkins CA, Magill SS, and See I
- Subjects
- Humans, Klebsiella pneumoniae genetics, beta-Lactamases genetics, Escherichia coli genetics, Microbial Sensitivity Tests, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Escherichia coli Infections epidemiology, Escherichia coli Infections drug therapy, Klebsiella Infections epidemiology, Klebsiella Infections drug therapy
- Abstract
Objective: The incidence of infections from extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-E) is increasing in the United States. We describe the epidemiology of ESBL-E at 5 Emerging Infections Program (EIP) sites., Methods: During October-December 2017, we piloted active laboratory- and population-based (New York, New Mexico, Tennessee) or sentinel (Colorado, Georgia) ESBL-E surveillance. An incident case was the first isolation from normally sterile body sites or urine of Escherichia coli or Klebsiella pneumoniae/oxytoca resistant to ≥1 extended-spectrum cephalosporin and nonresistant to all carbapenems tested at a clinical laboratory from a surveillance area resident in a 30-day period. Demographic and clinical data were obtained from medical records. The Centers for Disease Control and Prevention (CDC) performed reference antimicrobial susceptibility testing and whole-genome sequencing on a convenience sample of case isolates., Results: We identified 884 incident cases. The estimated annual incidence in sites conducting population-based surveillance was 199.7 per 100,000 population. Overall, 800 isolates (96%) were from urine, and 790 (89%) were E. coli . Also, 393 cases (47%) were community-associated. Among 136 isolates (15%) tested at the CDC, 122 (90%) met the surveillance definition phenotype; 114 (93%) of 122 were shown to be ESBL producers by clavulanate testing. In total, 111 (97%) of confirmed ESBL producers harbored a bla
CTX-M gene. Among ESBL-producing E. coli isolates, 52 (54%) were ST131; 44% of these cases were community associated., Conclusions: The burden of ESBL-E was high across surveillance sites, with nearly half of cases acquired in the community. EIP has implemented ongoing ESBL-E surveillance to inform prevention efforts, particularly in the community and to watch for the emergence of new ESBL-E strains.- Published
- 2022
- Full Text
- View/download PDF
40. Whole-Genome Sequencing Reveals Diversity of Carbapenem-Resistant Pseudomonas aeruginosa Collected through CDC's Emerging Infections Program, United States, 2016-2018.
- Author
-
Stanton RA, Campbell D, McAllister GA, Breaker E, Adamczyk M, Daniels JB, Lutgring JD, Karlsson M, Schutz K, Jacob JT, Wilson LE, Vaeth E, Li L, Lynfield R, Snippes Vagnone PM, Phipps EC, Hancock EB, Dumyati G, Tsay R, Cassidy PM, Mounsey J, Grass JE, Bulens SN, Walters MS, and Halpin AL
- Subjects
- Anti-Bacterial Agents pharmacology, Bacterial Proteins genetics, Bacterial Proteins metabolism, Centers for Disease Control and Prevention, U.S., Humans, Microbial Sensitivity Tests, Multilocus Sequence Typing, Porins genetics, United States epidemiology, beta-Lactamases genetics, beta-Lactamases metabolism, Pseudomonas Infections drug therapy, Pseudomonas Infections epidemiology, Pseudomonas aeruginosa
- Abstract
The CDC's Emerging Infections Program (EIP) conducted population- and laboratory-based surveillance of US carbapenem-resistant Pseudomonas aeruginosa (CRPA) from 2016 through 2018. To characterize the pathotype, 1,019 isolates collected through this project underwent antimicrobial susceptibility testing and whole-genome sequencing. Sequenced genomes were classified using the seven-gene multilocus sequence typing (MLST) scheme and a core genome (cg)MLST scheme was used to determine phylogeny. Both chromosomal and horizontally transmitted mechanisms of carbapenem resistance were assessed. There were 336 sequence types (STs) among the 1,019 sequenced genomes, and the genomes varied by an average of 84.7% of the cgMLST alleles used. Mutations associated with dysfunction of the porin OprD were found in 888 (87.1%) of the genomes and were correlated with carbapenem resistance, and a machine learning model incorporating hundreds of genetic variations among the chromosomal mechanisms of resistance was able to classify resistant genomes. While only 7 (0.1%) isolates harbored carbapenemase genes, 66 (6.5%) had acquired non-carbapenemase β-lactamase genes, and these were more likely to have OprD dysfunction and be resistant to all carbapenems tested. The genetic diversity demonstrates that the pathotype includes a variety of strains, and clones previously identified as high-risk make up only a minority of CRPA strains in the United States. The increased carbapenem resistance in isolates with acquired non-carbapenemase β-lactamase genes suggests that horizontally transmitted mechanisms aside from carbapenemases themselves may be important drivers of the spread of carbapenem resistance in P. aeruginosa.
- Published
- 2022
- Full Text
- View/download PDF
41. Practices and activities among healthcare personnel with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection working in different healthcare settings-ten Emerging Infections Program sites, April-November 2020.
- Author
-
Chea N, Eure T, Penna AR, Brown CJ, Nadle J, Godine D, Frank L, Czaja CA, Johnston H, Barter D, Miller BF, Angell K, Marshall K, Meek J, Brackney M, Carswell S, Thomas S, Wilson LE, Perlmutter R, Marceaux-Galli K, Fell A, Lim S, Lynfield R, Davis SS, Phipps EC, Sievers M, Dumyati G, Concannon C, McCullough K, Woods A, Seshadri S, Myers C, Pierce R, Ocampo VLS, Guzman-Cottrill JA, Escutia G, Samper M, Pena SA, Adre C, Groenewold M, Thompson ND, and Magill SS
- Subjects
- Delivery of Health Care, Health Personnel, Humans, Personnel, Hospital, Skilled Nursing Facilities, COVID-19 epidemiology, SARS-CoV-2
- Abstract
Healthcare personnel with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection were interviewed to describe activities and practices in and outside the workplace. Among 2,625 healthcare personnel, workplace-related factors that may increase infection risk were more common among nursing-home personnel than hospital personnel, whereas selected factors outside the workplace were more common among hospital personnel.
- Published
- 2022
- Full Text
- View/download PDF
42. Molecular Characterization of Carbapenem-Resistant Enterobacterales Collected in the United States.
- Author
-
Karlsson M, Lutgring JD, Ansari U, Lawsin A, Albrecht V, McAllister G, Daniels J, Lonsway D, McKay L, Beldavs Z, Bower C, Dumyati G, Gross A, Jacob J, Janelle S, Kainer MA, Lynfield R, Phipps EC, Schutz K, Wilson L, Witwer ML, Bulens SN, Walters MS, Duffy N, Kallen AJ, Elkins CA, and Rasheed JK
- Subjects
- Anti-Bacterial Agents pharmacology, Bacterial Proteins genetics, Enterobacter, Escherichia coli genetics, Humans, Klebsiella pneumoniae genetics, Microbial Sensitivity Tests, United States, beta-Lactamases genetics, Carbapenems pharmacology, Enterobacteriaceae Infections drug therapy, Enterobacteriaceae Infections epidemiology
- Abstract
Carbapenem-resistant Enterobacterales (CRE) are a growing public health concern due to resistance to multiple antibiotics and potential to cause health care-associated infections with high mortality. Carbapenemase-producing CRE are of particular concern given that carbapenemase-encoding genes often are located on mobile genetic elements that may spread between different organisms and species. In this study, we performed phenotypic and genotypic characterization of CRE collected at eight U.S. sites participating in active population- and laboratory-based surveillance of carbapenem-resistant organisms. Among 421 CRE tested, the majority were isolated from urine ( n = 349, 83%). Klebsiella pneumoniae was the most common organism ( n = 265, 63%), followed by Enterobacter cloacae complex ( n = 77, 18%) and Escherichia coli ( n = 50, 12%). Of 419 isolates analyzed by whole genome sequencing, 307 (73%) harbored a carbapenemase gene; variants of bla
KPC predominated ( n = 299, 97%). The occurrence of carbapenemase-producing K. pneumoniae , E. cloacae complex, and E. coli varied by region; the predominant sequence type within each genus was ST258, ST171, and ST131, respectively. None of the carbapenemase-producing CRE isolates displayed resistance to all antimicrobials tested; susceptibility to amikacin and tigecycline was generally retained.- Published
- 2022
- Full Text
- View/download PDF
43. Genomic Analysis of Clostridioides difficile in 2 Regions of the United States Reveals a Diversity of Strains and Limited Transmission.
- Author
-
Pecora N, Holzbauer S, Wang X, Gu Y, Taffner S, Hatwar T, Hardy D, Dziejman M, D'Heilly P, Pung K, Guh A, Qiu X, Gill S, and Dumyati G
- Subjects
- Clostridioides, Clostridium Infections microbiology, Cross Infection epidemiology, Genome, Genomics, Humans, Infectious Disease Transmission, Patient-to-Professional, Infectious Disease Transmission, Professional-to-Patient, Minnesota epidemiology, Multilocus Sequence Typing, New York epidemiology, Population Surveillance, United States epidemiology, Clostridioides difficile genetics, Clostridium Infections epidemiology, Clostridium Infections transmission, Hospitalization statistics & numerical data, Whole Genome Sequencing
- Abstract
Background: The distribution of Clostridioides difficile strains and transmission dynamics in the United States are not well defined. Whole-genome sequencing across 2 Centers for Disease Control and Prevention Emerging Infections Program C. difficile infection (CDI) surveillance regions (Minnesota and New York) was performed to identify predominant multilocus sequence types (MLSTs) in community-associated (CA) and healthcare-associated (HCA) disease and assess transmission., Methods: Whole-genome sequencing was performed on C. difficile isolates from patients with CDI over 3 months between 2016 and 2017. Patients were residents of the catchment area without a positive C. difficile test in the preceding 8 weeks. CDI cases were epidemiologically classified as HCA or CA., Results: Of 422 isolates, 212 (50.2%) were HCA and 203 (48.1%) were CA. Predominant MLSTs were sequence type (ST) 42 (9.3%), ST8 (7.8%), and ST2 (8.1%). MLSTs associated with HCA-CDI included ST1 (76%), ST53 (83.3%), and ST43 (80.0%), while those associated with CA-CDI included ST3 (76.9%) and ST41 (77.8%). ST1 was more frequent in New York than in Minnesota (10.8% vs 3.1%). Thirty-three pairs were closely related genomically, 14 of which had potential patient-to-patient transmission supported by record review., Conclusions: The genomic epidemiology of C. difficile across 2 regions of the United States indicates the presence of a diverse strain profile and limited direct transmission., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
44. Risk Factors for SARS-CoV-2 Infection Among US Healthcare Personnel, May-December 2020.
- Author
-
Chea N, Brown CJ, Eure T, Ramirez RA, Blazek G, Penna AR, Li R, Czaja CA, Johnston H, Barter D, Miller BF, Angell K, Marshall KE, Fell A, Lovett S, Lim S, Lynfield R, Davis SS, Phipps EC, Sievers M, Dumyati G, Concannon C, McCullough K, Woods A, Seshadri S, Myers C, Pierce R, Ocampo VLS, Guzman-Cottrill JA, Escutia G, Samper M, Thompson ND, Magill SS, and Grigg CT
- Subjects
- Activities of Daily Living, Delivery of Health Care, Health Personnel, Humans, Risk Factors, SARS-CoV-2, COVID-19, Occupational Exposure
- Abstract
To determine risk factors for coronavirus disease (COVID-19) among US healthcare personnel (HCP), we conducted a case-control analysis. We collected data about activities outside the workplace and COVID-19 patient care activities from HCP with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test results (cases) and from HCP with negative test results (controls) in healthcare facilities in 5 US states. We used conditional logistic regression to calculate adjusted matched odds ratios and 95% CIs for exposures. Among 345 cases and 622 controls, factors associated with risk were having close contact with persons with COVID-19 outside the workplace, having close contact with COVID-19 patients in the workplace, and assisting COVID-19 patients with activities of daily living. Protecting HCP from COVID-19 may require interventions that reduce their exposures outside the workplace and improve their ability to more safely assist COVID-19 patients with activities of daily living.
- Published
- 2022
- Full Text
- View/download PDF
45. Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel.
- Author
-
Pilishvili T, Gierke R, Fleming-Dutra KE, Farrar JL, Mohr NM, Talan DA, Krishnadasan A, Harland KK, Smithline HA, Hou PC, Lee LC, Lim SC, Moran GJ, Krebs E, Steele MT, Beiser DG, Faine B, Haran JP, Nandi U, Schrading WA, Chinnock B, Henning DJ, Lovecchio F, Lee J, Barter D, Brackney M, Fridkin SK, Marceaux-Galli K, Lim S, Phipps EC, Dumyati G, Pierce R, Markus TM, Anderson DJ, Debes AK, Lin MY, Mayer J, Kwon JH, Safdar N, Fischer M, Singleton R, Chea N, Magill SS, Verani JR, and Schrag SJ
- Subjects
- Adolescent, Adult, Aged, COVID-19 diagnosis, COVID-19 ethnology, COVID-19 Serological Testing, Case-Control Studies, Female, Humans, Immunization, Secondary, Male, Middle Aged, Polymerase Chain Reaction, United States, 2019-nCoV Vaccine mRNA-1273 administration & dosage, BNT162 Vaccine administration & dosage, COVID-19 prevention & control, Health Personnel, Vaccine Efficacy
- Abstract
Background: The prioritization of U.S. health care personnel for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), allowed for the evaluation of the effectiveness of these new vaccines in a real-world setting., Methods: We conducted a test-negative case-control study involving health care personnel across 25 U.S. states. Cases were defined on the basis of a positive polymerase-chain-reaction (PCR) or antigen-based test for SARS-CoV-2 and at least one Covid-19-like symptom. Controls were defined on the basis of a negative PCR test for SARS-CoV-2, regardless of symptoms, and were matched to cases according to the week of the test date and site. Using conditional logistic regression with adjustment for age, race and ethnic group, underlying conditions, and exposures to persons with Covid-19, we estimated vaccine effectiveness for partial vaccination (assessed 14 days after receipt of the first dose through 6 days after receipt of the second dose) and complete vaccination (assessed ≥7 days after receipt of the second dose)., Results: The study included 1482 case participants and 3449 control participants. Vaccine effectiveness for partial vaccination was 77.6% (95% confidence interval [CI], 70.9 to 82.7) with the BNT162b2 vaccine (Pfizer-BioNTech) and 88.9% (95% CI, 78.7 to 94.2) with the mRNA-1273 vaccine (Moderna); for complete vaccination, vaccine effectiveness was 88.8% (95% CI, 84.6 to 91.8) and 96.3% (95% CI, 91.3 to 98.4), respectively. Vaccine effectiveness was similar in subgroups defined according to age (<50 years or ≥50 years), race and ethnic group, presence of underlying conditions, and level of patient contact. Estimates of vaccine effectiveness were lower during weeks 9 through 14 than during weeks 3 through 8 after receipt of the second dose, but confidence intervals overlapped widely., Conclusions: The BNT162b2 and mRNA-1273 vaccines were highly effective under real-world conditions in preventing symptomatic Covid-19 in health care personnel, including those at risk for severe Covid-19 and those in racial and ethnic groups that have been disproportionately affected by the pandemic. (Funded by the Centers for Disease Control and Prevention.)., (Copyright © 2021 Massachusetts Medical Society.)
- Published
- 2021
- Full Text
- View/download PDF
46. Mandating COVID-19 Vaccine for Nursing Home Staff: An Ethical Obligation.
- Author
-
Dumyati G, Jump RLP, and Gaur S
- Subjects
- COVID-19 Vaccines, Humans, Nursing Homes, SARS-CoV-2, COVID-19, Nursing Staff
- Published
- 2021
- Full Text
- View/download PDF
47. Association between Socioeconomic Status and Incidence of Community-Associated Clostridioides difficile Infection - United States, 2014-2015.
- Author
-
Skrobarcek KA, Mu Y, Ahern J, Basiliere E, Beldavs ZG, Brousseau G, Dumyati G, Fridkin S, Holzbauer SM, Johnston H, Kainer MA, Meek J, Ocampo VLS, Parker E, Perlmutter R, Phipps EC, Winston L, and Guh A
- Subjects
- Clostridioides, Humans, Incidence, Social Class, United States epidemiology, Clostridioides difficile, Clostridium Infections epidemiology
- Abstract
We evaluated the association between socioeconomic status (SES) and community-associated Clostridioides difficile infection (CA-CDI) incidence across 2474 census tracts in 10 states. Highly correlated community-level SES variables were transformed into distinct factors using factor analysis. We found low SES communities were associated with higher CA-CDI incidence., (Published by Oxford University Press for the Infectious Diseases Society of America 2021.)
- Published
- 2021
- Full Text
- View/download PDF
48. Urinary tract infection stewardship: A urinary antibiogram and electronic medical record alert nudging narrower-spectrum antibiotics for urinary tract infections.
- Author
-
Laguio-Vila M, Staicu ML, Brundige ML, Alcantara J, Yang H, Lautenbach E, and Dumyati G
- Abstract
An antimicrobial stewardship intervention consisting of a urinary antibiogram and an electronic health record best-practice advisory promoted narrower-spectrum antibiotics for uncomplicated urinary tract infections in hospitalized patients. Over 20 months, the intervention significantly reduced ceftriaxone orders by 48% ( P < .001) and increased cefazolin use 19 times from baseline ( P < .001)., Competing Interests: All authors report no conflicts of interest relevant to this article., (© The Society for Healthcare Epidemiology of America 2021.)
- Published
- 2021
- Full Text
- View/download PDF
49. Detection of CTX-M-27 β-Lactamase Genes on Two Distinct Plasmid Types in ST38 Escherichia coli from Three U.S. States.
- Author
-
Cameron A, Mangat R, Mostafa HH, Taffner S, Wang J, Dumyati G, Stanton RA, Daniels JB, Campbell D, Lutgring JD, and Pecora ND
- Subjects
- Escherichia coli genetics, Humans, Plasmids genetics, United States, beta-Lactamases genetics, Escherichia coli Infections drug therapy, Escherichia coli Proteins genetics
- Abstract
Infections caused by extended-spectrum-β-lactamase (ESBL)-producing Escherichia coli are a significant cause of morbidity and health care costs. Globally, the prevailing clonal type is ST131 in association with the bla
CTX-M-15 β-lactamase gene. However, other ESBLs, such as blaCTX-M-14 and blaCTX-M-27 , can also be prevalent in some regions. We identified ST38 ESBL-producing E. coli from different regions in the United States which carry blaCTX-M-27 embedded on two distinct plasmid types, suggesting the potential emergence of new ESBL lineages.- Published
- 2021
- Full Text
- View/download PDF
50. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021.
- Author
-
Pilishvili T, Fleming-Dutra KE, Farrar JL, Gierke R, Mohr NM, Talan DA, Krishnadasan A, Harland KK, Smithline HA, Hou PC, Lee LC, Lim SC, Moran GJ, Krebs E, Steele M, Beiser DG, Faine B, Haran JP, Nandi U, Schrading WA, Chinnock B, Henning DJ, LoVecchio F, Nadle J, Barter D, Brackney M, Britton A, Marceaux-Galli K, Lim S, Phipps EC, Dumyati G, Pierce R, Markus TM, Anderson DJ, Debes AK, Lin M, Mayer J, Babcock HM, Safdar N, Fischer M, Singleton R, Chea N, Magill SS, Verani J, and Schrag S
- Subjects
- Adult, Aged, COVID-19 epidemiology, COVID-19 Testing, COVID-19 Vaccines administration & dosage, Case-Control Studies, Female, Humans, Immunization Schedule, Male, Middle Aged, Occupational Diseases epidemiology, United States epidemiology, Young Adult, COVID-19 prevention & control, COVID-19 Vaccines immunology, Health Personnel statistics & numerical data, Occupational Diseases prevention & control
- Abstract
Throughout the COVID-19 pandemic, health care personnel (HCP) have been at high risk for exposure to SARS-CoV-2, the virus that causes COVID-19, through patient interactions and community exposure (1). The Advisory Committee on Immunization Practices recommended prioritization of HCP for COVID-19 vaccination to maintain provision of critical services and reduce spread of infection in health care settings (2). Early distribution of two mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) to HCP allowed assessment of the effectiveness of these vaccines in a real-world setting. A test-negative case-control study is underway to evaluate mRNA COVID-19 vaccine effectiveness (VE) against symptomatic illness among HCP at 33 U.S. sites across 25 U.S. states. Interim analyses indicated that the VE of a single dose (measured 14 days after the first dose through 6 days after the second dose) was 82% (95% confidence interval [CI] = 74%-87%), adjusted for age, race/ethnicity, and underlying medical conditions. The adjusted VE of 2 doses (measured ≥7 days after the second dose) was 94% (95% CI = 87%-97%). VE of partial (1-dose) and complete (2-dose) vaccination in this population is comparable to that reported from clinical trials and recent observational studies, supporting the effectiveness of mRNA COVID-19 vaccines against symptomatic disease in adults, with strong 2-dose protection., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Deverick Anderson is the owner of Infection Control Education for Major Sports, LLC, and reports grants from the Agency for Healthcare Research and Quality and personal fees from UpToDate, outside the submitted work. Ghinwa Dumyati reports grants from Pfizer and personal fees from Roche Diagnostics. Gregory Moran reports grants from I-Mab Biopharma and BeiGene and personal fees from Light AI. Mark Steele reports personal fees from Light AI, during the conduct of the study. No other potential conflicts of interest were disclosed.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.